In case you missed it, STAT is hosting a virtual event this March focused on the emergence and significance of biosimilars on the health care industry.
At our upcoming March of the Biosimilarsevent,STAT's Ed Silverman, Pharmalot columnist and senior writer, will be leading a discussion with a panel of experts on the rise of new biosimilars entering the U.S. market—most notably, biosimilar versions of Humira, which for years has been the world's best-selling medicine.
What does this mean for insurance coverage, the way drug makers market these medicines, and what is the broader impact on patients and the industry? We'll discuss!
This event is free for all to attend. For more details on our March panelists and to RSVP, click the link below!
.jpg?width=1200&upscale=true&name=0314_MOBS_TallEmail%20(1).jpg)
No comments